Computational chemistry

Terramera Creates enrichAg to Commercialize Transformative Soil Analysis Platform with $6M from At One Ventures

Retrieved on: 
Thursday, January 12, 2023
Carbon, Climate change, Farmer, Potassium, Digital, AOV, Intelligence engine, Soil, Version One Ventures, Machine learning, Knowledge, Health, Phosphorus, Partnership, Calibration, VC, Drought, Computational chemistry, Nitrogen, IP, USD, Agriculture, Fertilizer

EnrichSoil can be used to optimize fertilizer use and to understand and improve soil health, the most essential component of the global food system.

Key Points: 
  • EnrichSoil can be used to optimize fertilizer use and to understand and improve soil health, the most essential component of the global food system.
  • The key is timely, accurate and affordable analysis of soils," said Terramera Founder & CEO, Karn Manhas.
  • "EnrichSoil produces accurate maps of soil fertility and carbon across fields  ato show how healthy the soil and farm profits can become," said Manhas.
  • EnrichAg completed its first close of its seed funding with At One Ventures.

STORM Therapeutics Expands R&D Leadership Team

Retrieved on: 
Tuesday, January 10, 2023
Storm, Cancer, Clinical trial, Cambridge Crystallographic Data Centre, Celltech, CMC, Computational chemistry, Drug discovery, Therapy, University of Cambridge, University, UCB, Enzyme, RME, Trial of the century, Royal Society, Patient, Ophthalmology, Neurology, Royal Society of Chemistry, Columbia University, Medicinal chemistry, UCLA, METTL3, Patent, Bachelor of Science, Senior, Doctor of Philosophy, RNA, Nobel Prize, DMPK, Pharmaceutical industry, Chemistry

Matthew will work with the leadership team to progress STORM's pipeline while working with functional heads and project leaders to define medicinal chemistry, drug discovery, DMPK, PK–PD, CMC and preclinical development strategies.

Key Points: 
  • Matthew will work with the leadership team to progress STORM's pipeline while working with functional heads and project leaders to define medicinal chemistry, drug discovery, DMPK, PK–PD, CMC and preclinical development strategies.
  • Newly promoted Vice President of Medicinal Chemistry, Beth Thomas has over 20 years of experience in medicinal and computational chemistry and joined STORM Therapeutics in 2016.
  • Oliver Rausch, Chief Scientific Officer of STORM Therapeutics, said: "I am delighted to welcome Matthew to the leadership team at STORM.
  • Matthew Fyfe, Senior Vice President of STORM Therapeutics, commented: "I am excited to be joining this strong and experienced drug discovery and development team.

STORM Therapeutics Expands R&D Leadership Team

Retrieved on: 
Tuesday, January 10, 2023
Storm, Cancer, Clinical trial, Cambridge Crystallographic Data Centre, Celltech, CMC, Computational chemistry, Drug discovery, Therapy, University of Cambridge, University, UCB, Enzyme, RME, Trial of the century, Royal Society, Patient, Ophthalmology, Neurology, Royal Society of Chemistry, Columbia University, Medicinal chemistry, UCLA, METTL3, Patent, Bachelor of Science, Senior, Doctor of Philosophy, RNA, Nobel Prize, DMPK, Pharmaceutical industry, Chemistry

Matthew will work with the leadership team to progress STORM's pipeline while working with functional heads and project leaders to define medicinal chemistry, drug discovery, DMPK, PK–PD, CMC and preclinical development strategies.

Key Points: 
  • Matthew will work with the leadership team to progress STORM's pipeline while working with functional heads and project leaders to define medicinal chemistry, drug discovery, DMPK, PK–PD, CMC and preclinical development strategies.
  • Newly promoted Vice President of Medicinal Chemistry, Beth Thomas has over 20 years of experience in medicinal and computational chemistry and joined STORM Therapeutics in 2016.
  • Oliver Rausch, Chief Scientific Officer of STORM Therapeutics, said: "I am delighted to welcome Matthew to the leadership team at STORM.
  • Matthew Fyfe, Senior Vice President of STORM Therapeutics, commented: "I am excited to be joining this strong and experienced drug discovery and development team.

Inventiva draws down €25 million tranche under Finance Contract with the European Investment Bank

Retrieved on: 
Monday, December 12, 2022
Finance, Mucopolysaccharidosis, IVA, Factor X, Pharmacology, Partnership, Food, Sale, Chronic liver disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MPS, NASH, Pharmacokinetics, European Investment Bank, ISIN, Fruit, Exercise, EIB, Commercial code, Fatty liver disease, Research, Computational chemistry, Sino Biopharmaceutical Limited, Biology, ATM, Patient, MPS VI, Pharmaceutical industry, Security (finance), Euronext Paris

Jean Volatier, Chief Financial Officer of Inventiva, stated: “We are pleased to see that our long-term partnership with the EIB is bearing fruit.

Key Points: 
  • Jean Volatier, Chief Financial Officer of Inventiva, stated: “We are pleased to see that our long-term partnership with the EIB is bearing fruit.
  • Any drawings under the terms of the Finance Contract that have not been disbursed within 36 months from the signing of the Finance Contract, (i.e., before May 16, 2025), cannot be completed at a later date.
  • On November 4, 2022, the Company received an upfront payment of $12 million under its collaboration agreement with Sino Biopharm.
  • on December 8, 2026), (ii) a change of control event, (iii) an event of default under the Finance Contract, or (iv) a repayment demand by EIB under the Finance Contract.

Ajax Therapeutics Presents Preclinical Data on AJ1-10502, a Next Generation Type II JAK2 Inhibitor, at the American Society of Hematology Annual Meeting

Retrieved on: 
Monday, December 12, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Health Technology, Clinical Trials, Therapy, Pancreatic serous cystadenoma, Spleen, MD, Poster, Doctor of Philosophy, Drug discovery, Society, Research, MPN, Patient, Translational research, MSK, Ajax, Myeloproliferative neoplasm, Memorial Sloan Kettering Cancer Center, Type, Type 2, Disease, Reticulocyte, JAK2, Bone marrow, Senior, Computational chemistry, Hematocrit, Secondary research, ASH, Pharmaceutical industry, Primary myelofibrosis, Leukemia

In preclinical studies, investigational Type II JAK2 inhibitors have been shown to overcome disease persistence to ruxolitinib and, most significantly, reduce mutant JAK2 allele burden that drives MPN disease progression.

Key Points: 
  • In preclinical studies, investigational Type II JAK2 inhibitors have been shown to overcome disease persistence to ruxolitinib and, most significantly, reduce mutant JAK2 allele burden that drives MPN disease progression.
  • Were very encouraged by the first preclinical data on our Type II JAK2 inhibitor program being presented today at the ASH Annual Meeting, said Craig E. Masse, PhD, Senior Vice President, Discovery Research at Ajax Therapeutics.
  • This data supports our findings that Type II JAK2 inhibitors can significantly reduce the mutant allele burden that drives MPNs which is not observed with Type I JAK2 inhibitors, such as ruxolitinib.
  • Ajax Therapeutics , Inc. is pursuing uniquely selective approaches to develop novel first-in-class therapeutics for myeloproliferative neoplasms (MPNs), including Myelofibrosis.

Ajax Therapeutics Appoints Srdan “Serge” Verstovsek, MD, PhD, to Scientific Advisory Board

Retrieved on: 
Tuesday, December 6, 2022
Oncology, Health, Health Technology, Research, Science, Pharmaceutical, Biotechnology, Therapy, Pancreatic serous cystadenoma, Srđan, MD, Doctor of Philosophy, Drug discovery, Society, Research, MPN, Patient, Translational research, Section, International Work Group for Indigenous Affairs, MD Anderson Cancer Center, MSK, Ajax, Memorial Sloan Kettering Cancer Center, Myeloproliferative neoplasm, Division, Executive Committee, School of Dental Medicine, University of Zagreb, Committee, JAK2, American Society for Clinical Investigation, University, Computational chemistry, SAB, Pharmaceutical industry, Primary myelofibrosis, Leukemia

Ajax Therapeutics, Inc., a biopharmaceutical company applying computational chemistry and structure-based technologies to develop novel small molecules for myeloproliferative neoplasms (MPNs), today announced the appointment of Srdan Serge Verstovsek, MD, PhD, to the Companys Scientific Advisory Board (SAB).

Key Points: 
  • Ajax Therapeutics, Inc., a biopharmaceutical company applying computational chemistry and structure-based technologies to develop novel small molecules for myeloproliferative neoplasms (MPNs), today announced the appointment of Srdan Serge Verstovsek, MD, PhD, to the Companys Scientific Advisory Board (SAB).
  • I am pleased to be joining the Ajax SAB at this exciting stage of the companys development, said Dr. Verstovsek.
  • Ajax Therapeutics, Inc. is pursuing uniquely selective approaches to develop novel first-in-class therapeutics for myeloproliferative neoplasms (MPNs), including Myelofibrosis.
  • NOTE: Dr. Ross Levine serves on the board of directors of, has provided advisory services for, and has equity interests in Ajax Therapeutics.

Congruence Therapeutics to Present at the January 2023 Biotech Showcase in San Francisco

Retrieved on: 
Wednesday, December 7, 2022
Biotechnology, Therapy, JPM, Biotechnology Innovation Organization, Conference, J. P. Morgan, Protein, Drug discovery, Biophysics, Congruence, AI, Computational chemistry, SAN, Machine learning, BIO, Pharmaceutical industry

SAN DIEGO, Dec. 7, 2022 /PRNewswire/ -- Congruence Therapeutics, a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding, announced today that Congruence's CEO, Dr.Clarissa Desjardins, will present a corporate overview at the Biotech Showcase 2023 meeting on Monday, January 9, 2023, at 3:30 PM.

Key Points: 
  • SAN DIEGO, Dec. 7, 2022 /PRNewswire/ -- Congruence Therapeutics, a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding, announced today that Congruence's CEO, Dr.Clarissa Desjardins, will present a corporate overview at the Biotech Showcase 2023 meeting on Monday, January 9, 2023, at 3:30 PM.
  • The Biotech Showcase Conference is taking place inSan Franciscoin parallel to the J.P. Morgan (JPM) 41stAnnual HealthCare Conference.
  • Our ground-breaking discovery engine, RevenirTM, can reproduce the pathogenic state of disease and discover functional allosteric and cryptic pockets with an unprecedented timing and hit rate.
  • RevenirTM sees proteins in ways others have been unable to see - in their full dynamic state.

Congruence Therapeutics Strengthens Leadership Team with Appointment of Dr. Sharath Hegde as Chief Scientific Officer

Retrieved on: 
Tuesday, November 22, 2022
Chief business officer, Ecosystem, Growth, NCE, Doctor of Philosophy, Biophysics, Congruence, Acquisition, Queen's University, Biotechnology, University, Senior, BMS, Roche, Amgen, Series, Therapy, Bristol Myers Squibb, EVP, Herophilos, Rutgers University, Flagship Pioneering, Celgene, Syntex, Cell biology, Drug discovery, Business development, Corporation, Protein, Mace Head Atmospheric Research Station, Computational chemistry, Disease, Machine learning, Pharmaceutical industry, Fine chemical, Research, Recursion, Pharmacology, Flagship, Biology

MONTREAL, Nov. 22, 2022 /PRNewswire/ -- Congruence Therapeutics, a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding, announced today the appointment of Sharath S. Hegde, Ph.D. as Chief Scientific Officer. 

Key Points: 
  • "I am thrilled to welcome Sharath to Congruence as Chief Scientific Officer.
  • Prior to joining Congruence, Dr. Hegde was Chief Scientific Officer at Herophilus, a technology enabled neurotherapeutics company, where he established the company's drug-discovery strategy and advanced their Rett syndrome project into late discovery.
  • Before that, Sharath was Chief Scientific Officer of Recursion, a machine-learning and technology-enabled clinical-stage biotechnology company with a broad pipeline.
  • Dr. Borsuk joins Congruence from Sitryx Therapeutics, where she served as Chief Business Officer.

Inventiva reports 2022 Third Quarter Financial Information¹

Retrieved on: 
Thursday, November 10, 2022
USD, Adult, Fatty liver disease, DC, Nasdaq, NASH, Research, Biology, EIB, ISIN, Obesity, VI, Drug development, MA, Chronic liver disease, Phase, Mucopolysaccharidosis, Computational chemistry, Pharmacokinetics, Company, Factor X, Pharmacology, Conference, Psoriasis, Patient, Sino Biopharmaceutical Limited, AbbVie, MPS, FDA, Pharmaceutical industry, Medical device, Cryptocurrency, Bank, Euronext Paris

As of September 30, 2022, Inventivas cash position stood at 72.6 million, compared to 87.2 million as

Key Points: 
  • As of September 30, 2022, Inventivas cash position stood at 72.6 million, compared to 87.2 million as
    of June 30, 2022 and 95.4 million as of December 31, 2021.
  • R&D expenses, mainly driven by the development of lanifibranor in NASH, were up 27% compared to the same period in 2021.
  • The Companys development agreement with Sino Biopharm was executed on September 21, 2022 as previously announced and the $12.6 million upfront payment was received on November 4, 2022.
  • Inventiva is also in the process of selecting an oncology development candidate for its Hippo signaling pathway program.

DoubleRainbow Biosciences Announces Strategic AI Collaboration with Galixir

Retrieved on: 
Monday, November 7, 2022
Chemistry, Computational chemistry, Protein, M1, Synthetic biology, Therapy, Network, Algorithm, AI, Biology, GLOBE, Metabolomics, Physics, Artificial intelligence, Nature, CEO, Organization, Double Rainbow, BioRxiv, Environment, Partnership, Health, Genomics, Deep learning, PRISM, Drug discovery, Double, Fine chemical, Pharmaceutical industry

With this agreement, Double Rainbow and Galixir will combine their respective expertise and technologies to pioneer new capabilities for natural product pathway elucidation and enzyme function prediction.

Key Points: 
  • With this agreement, Double Rainbow and Galixir will combine their respective expertise and technologies to pioneer new capabilities for natural product pathway elucidation and enzyme function prediction.
  • Our goal is to provide ethical, cost-effective access to rare or endangered natural products that support human health and wellbeing.
  • By collaborating with Double Rainbow and leveraging their advanced platforms HARMONY and PRISM, our unique models will be fueled with unique data.
  • Galixir is a global leader integrating drug discovery and AI with the mission to build a healthier world and make innovative medicines available.